Clinical Study to Evaluate Tolerability and Safety of ARK-E021 Foam and to Monitor Clinical Effect in Acne Vulgaris Patients

Main Inclusion Criteria: * Patient is male or female between the ages of 12 to 40. * A clinical diagnosis of acne vulgaris with facial involvement. * Minimum of 15 inflammatory lesions on the face (papules and/ or pustules)but not more than 40. * Existence of non-inflammatory lesions on the face (opened and/or closed comedones). * A score of ≥2 (moderate) on the investigator's global assessment scale. * Use of non oral contraceptives in female of childbearing potential during the study. * No known medical conditions that, in the Investigator's opinion could interfere with study participation. * Patient is willing and able to comply with all the requirement of the study protocol. * Patient is willing and able to give written informed consent prior to participation in the study. Main Exclusion Criteria: * Acne conglobata, acne fulminans, secondary acne (chloracne, drug induced acne), or severe acne requiring systemic treatment. * One or more active nodule/cyst acne on the face (inactive lesions allowed). * Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere with diagnosis or assessment of acne vulgaris. * Participation in another investigational drug trial within 30 days prior to study entry. * Concomitant medication: * Use of systemic steroids, systemic antibiotics, systemic treatment for acne vulgaris, systemic anti-inflammatory agents within 4 weeks prior to baseline or during the study. * Use of topical steroids, topical antibiotics, topical treatment for acne vulgaris, topical anti-inflammatory agents within 2 weeks prior to baseline or during the study. * Treatment for acne with isotretinoin or isotretinoin derivatives within 12 months prior to study entry.